Stelara Shines in Three Year Crohn's Disease Study

Stelara Shines in Three Year Crohn's Disease Study

Source: 
CP Wire
snippet: 
  • 60.3% of all randomised ustekinumab-treated patients who entered the long-term extension study were in clinical remission at week 152
  • Of those patients who were naïve to TNF antagonist therapy and treated with ustekinumab, 67.6% were in clinical remission at week 156